National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4) (No. PB 36 of 2012)

Link to law: https://www.comlaw.gov.au/Details/F2012L01118

Subscribe to a Global-Regulation Premium Membership Today!

Key Benefits:

Subscribe Now
 
PB 36 of 2012
National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4)
 
National Health Act 1953
___________________________________________________________________________
 
I, FELICITY McNEILL, First Assistant Secretary, Pharmaceutical Benefits Division, Department of Health and Ageing, delegate of the Minister for Health, make this instrument under subsections 100(1) and (2) of the National Health Act 1953.
Dated                                          25 May 2012
 
 
 
 
 
 
 
 
 
 
 
FELICITY McNEILL
First Assistant Secretary
Pharmaceutical Benefits Division
Department of Health and Ageing
___________________________________________________________________
 
 
 
 
 
1              Name of Instrument
 
(1)                This Instrument is the National Health (Efficient Funding of Chemotherapy) Special Arrangement Amendment Instrument 2012 (No. 4).
 
(2)                This Instrument may also be cited as PB 36 of 2012.
 
2             Commencement
                This Instrument commences on 1 June 2012.
3              Amendments to PB 79 of 2011
                      Schedule 1 amends the National Health (Efficient Funding of Chemotherapy) Special Arrangement 2011 (PB 79 of 2011).
 
 
Schedule 1                   Amendments
 
 
[1]    Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 1 g (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection
insert in the columns in the order indicated:
 
 
 
Gemaccord
WQ
MP
 
D
 
[2]    Schedule 1 Part 1, after entry for Gemcitabine in the form Powder for I.V. infusion 200 mg (as hydrochloride) with manner of administration Injection and brand DBL Gemcitabine for Injection
insert in the columns in the order indicated:
 
 
 
Gemaccord
WQ
MP
 
D
 
[3]    Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL with manner of administration Injection and brand Hospira Pty Limited
insert in the columns in the order indicated:
 
 
 
Irinoccord
WQ
MP
C3184
D
 
[4]    Schedule 1 Part 1, after entry for Irinotecan in the form I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL with manner of administration Injection and brand Hospira Pty Limited
insert in the columns in the order indicated:
 
 
 
Irinoccord
WQ
MP
C3184
D
 
[5]    Schedule 1 Part 1, after entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 100 mg in 20 mL with manner of administration Injection and brand Eloxatin
insert in the columns in the order indicated:
 
 
 
Oxaliccord
WQ
MP
C3900 C3901 C3930 C3939
D
 
 
 
 
[6]    Schedule 1 Part 1, after entry for Oxaliplatin in the form Solution concentrate for I.V. infusion 50 mg in 10 mL with manner of administration Injection and brand Eloxatin
insert in the columns in the order indicated:
 
 
 
Oxaliccord
WQ
MP
C3900 C3901 C3930 C3939
D
 
Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003. 
See http://www.frli.gov.au.